Skip to main content

Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.

Publication ,  Journal Article
Batich, KA; Sampson, JH
Published in: Expert Opin Pharmacother
October 2014

INTRODUCTION: Malignant gliomas (MGs) represent the most common primary brain tumors in adults, the most deadly of which is grade IV glioblastoma. Patients with glioblastoma undergoing current standard-of-care therapy have a median survival of 12 - 15 months. AREAS COVERED: Over the past 25 years, there have been modest advancements in the treatment of MGs. Assessment of therapeutic responses has continued to evolve to account for the increasing number of agents being tested in the clinic. Currently approved therapies for primary tumors have been extended for use in the setting of recurrent disease with modest efficacy. Agents initially approved for recurrent gliomas have begun to demonstrate efficacy against de novo tumors but will ultimately need to be evaluated in future studies for scheduling, timing and dosing relative to chemotherapy. EXPERT OPINION: Screening and identification of tumor-specific mutations is critical for the advancement of effective therapy that is both safe and precise for the patient. Two unique antigens found in glioblastoma are currently being employed as targets for immunotherapeutic vaccines, one of which has advanced to Phase III testing. Whole genome sequencing of MGs has yielded two other novel mutations that offer great promise for the development of molecular inhibitors.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

October 2014

Volume

15

Issue

14

Start / End Page

2047 / 2061

Location

England

Related Subject Headings

  • Standard of Care
  • Pharmacology & Pharmacy
  • Neoplasm Recurrence, Local
  • Mutation
  • Humans
  • Glioma
  • Glioblastoma
  • Combined Modality Therapy
  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase II as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Batich, K. A., & Sampson, J. H. (2014). Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opin Pharmacother, 15(14), 2047–2061. https://doi.org/10.1517/14656566.2014.947266
Batich, Kristen A., and John H. Sampson. “Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.Expert Opin Pharmacother 15, no. 14 (October 2014): 2047–61. https://doi.org/10.1517/14656566.2014.947266.
Batich, Kristen A., and John H. Sampson. “Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.Expert Opin Pharmacother, vol. 15, no. 14, Oct. 2014, pp. 2047–61. Pubmed, doi:10.1517/14656566.2014.947266.

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

October 2014

Volume

15

Issue

14

Start / End Page

2047 / 2061

Location

England

Related Subject Headings

  • Standard of Care
  • Pharmacology & Pharmacy
  • Neoplasm Recurrence, Local
  • Mutation
  • Humans
  • Glioma
  • Glioblastoma
  • Combined Modality Therapy
  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase II as Topic